The Sapien transcatheter heart valve, pictured above, that Edwards Lifesciences introduced to the market after winning FDA approval in 2011 helped drive the company's business performance higher.

Last year, the California company's share price jumped 94%, to $127.38 from $65.76 at the end of 2013. As a result, the company added $6.4 billion to its market cap.